Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Redeye: Moberg Pharma Q4’2024 - All eyes on the European market

Moberg Pharma

Redeye views the Q4 report as uneventful in many respects, as most of the events were communicated during the quarter. The plan to launch in the EU is the same, and the path to the US is not closed, but it will take time, and the conditions have to be right. We add Norway and deduct S. Korea from our estimates. We must get further insight into how the EU market strategy will pan out during 2025 to make more significant changes. The current changes to our estimates increase our Base case to SEK 11 (9.5) per share. Following this report, we are changing the head analyst.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Moberg Pharma Q4’2024 - All eyes on the European market

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.